Simon Read Insider Profile
4 Followers
Simon Read, Director at Dianthus Therapeutics, holds 0.00 shares in Dianthus Therapeutics (Ticker: DNTH), holds 0.00 shares in Ra Pharmaceuticals (Ticker: RARX).
Simon Read has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Simon Read does not currently own shares as a corporate insider.
A breakdown of Simon Read's holdings
Insider Roles
Director
Roles that Simon Read holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Simon Read
Simon Read's Trading History
Dianthus Therapeutics
Aug 19, 2026
Director
Uninformative Buy
51.00K
$0.00
Ra Pharmaceuticals
Apr 03, 2020
―
Uninformative Sell
604.56K
$0.00
List of latest transactions for each holding click on a transaction to see Simon Read's performance on stock
You May Also Like
Simon Read insider profile FAQ
What is the percentage of profitable transactions made by Simon Read?
The percentage of profitable transactions made by Simon Read is ―.
What is the average return per transaction made by Simon Read?
The average return per transaction made by Simon Read is ―.
What stocks does Simon Read hold?
Simon Read holds: DNTH, RARX stocks.
What was Simon Read’s latest transaction?
Simon Read latest transaction was an Uninformative Buy of $51.00K.
What was Simon Read's most profitable transaction?
Simon Read’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Simon Read's role in Dianthus Therapeutics?
Simon Read's role in Dianthus Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.